# 04_QA_REPORT

# Quality Assurance Report

## Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0168 |
| Population Package | PP-0168 — EBV-associated Gastric Cancer + EBV Testing in Gastric Cancer |
| Version | 1.0.0 |
| QA Status | PASS — GOLD |

# Layer 1 — Content QA

| Check | Result |
|---|---|
| Single atomic clinical question | PASS |
| EBV-associated gastric cancer defined | PASS |
| EBV prevalence/association included | PASS |
| Clinicopathologic associations included | PASS |
| Tumor EBV status distinguished from EBV exposure | PASS |
| Testing role included | PASS |
| Morphology-triggered testing included | PASS |
| Prognostic uncertainty included | PASS |
| Immune-biology context included | PASS |
| Patient explanation included | PASS |
| Misconceptions addressed | PASS |

# Layer 2 — Clinical QA

| Check | Result |
|---|---|
| EBV recognized as strongly associated with gastric cancer | PASS |
| EBV-positive subgroup appropriately bounded | PASS |
| Proximal/diffuse/early-onset associations correctly framed | PASS |
| Routine EBV testing correctly rejected | PASS |
| Prominent lymphoid stroma correctly identified as testing trigger | PASS |
| EBV exposure not equated with tumor positivity | PASS |
| EBV status not presented as automatic treatment selector | PASS |
| Prognostic uncertainty preserved | PASS |
| Hereditary risk kept separate | PASS |
| Other biomarker packages kept separate | PASS |

# Layer 3 — Evidence QA

| Check | Result |
|---|---|
| NCCN Gastric Cancer v2.2026 reviewed | PASS |
| NCCN Gastric Cancer v2.2025 reviewed for corroborative context | PASS |
| NCI Prevention PDQ reviewed | PASS |
| NCI Treatment PDQ reviewed | PASS |
| ACS Stomach Cancer reviewed | PASS |
| PP Registry reviewed | PASS |
| Evidence hierarchy documented | PASS |
| Evidence matrix documented | PASS |
| Evidence gaps documented | PASS |
| Source traceability documented | PASS |

# Layer 4 — Educational QA

| Check | Result |
|---|---|
| Plain-language explanation | PASS |
| Common EBV exposure explained | PASS |
| Tumor-specific testing concept clear | PASS |
| No alarmist language | PASS |
| No deterministic causation claim | PASS |
| No deterministic prognosis claim | PASS |
| No automatic immunotherapy claim | PASS |
| No hereditary implication | PASS |

# Layer 5 — Boundary / Overlap QA

### PP-0178 — Histopathologic Classification
Detailed pathology remains delegated.

**Result: PASS**

### PP-0179 — Lauren Classification
Detailed intestinal/diffuse classification remains delegated.

**Result: PASS**

### PP-0180 — Gastric Cancer Molecular Classification
Broader molecular taxonomy remains delegated.

**Result: PASS**

### PP-0181 — HER2 Testing
HER2 remains separate.

**Result: PASS**

### PP-0182 — MSI/MMR Testing
MSI/MMR remains separate.

**Result: PASS**

### PP-0183 — PD-L1 Testing
PD-L1 testing and CPS remain separate.

**Result: PASS**

### PP-0184 — CLDN18.2 Testing
CLDN18.2 remains separate; EBV–CLDN18.2 relationship is not owned here.

**Result: PASS**

### PP-0187 — NGS Biomarker Testing
NGS methodology remains separate.

**Result: PASS**

### PP-0190 / PP-0191 — Treatment-oriented Biomarker Testing
Treatment-selection implications remain delegated.

**Result: PASS**

### PP-0149–PP-0159 — Hereditary Gastric Cancer
Germline/family testing remains separate.

**Result: PASS**

# Layer 6 — Safety QA

| Check | Result |
|---|---|
| No population EBV screening recommendation | PASS |
| No EBV blood-test diagnostic claim | PASS |
| No EBV vaccination/antiviral prevention claim | PASS |
| No laboratory protocol invented | PASS |
| No automatic immunotherapy recommendation | PASS |
| No individual EBV-based prognosis calculation | PASS |
| No hereditary-risk implication | PASS |
| No treatment recommendation outside scope | PASS |

# Layer 7 — Governance QA

| Check | Result |
|---|---|
| Approved Decision Batch respected | PASS |
| Gold Specification respected | PASS |
| Source-First workflow followed | PASS |
| Adjacent overlap reviewed | PASS |
| Four Gold artifacts completed | PASS |
| Boundary included in production response | PASS |
| Boundary placed only in production response | PASS |
| Versioning complete | PASS |
| Integration-ready structure | PASS |

# Boundary

**Core =** EBV-associated gastric cancer, EBV as a gastric-cancer-associated tumor factor, prevalence and clinicopathologic associations, proximal-stomach/diffuse-type/early-onset associations, tumor EBV status, distinction between EBV exposure and tumor EBV status, prognostic uncertainty, morphology-triggered EBV testing, current NCCN position that EBV testing is not routine but should be performed when prominent lymphoid stroma is present, interpretation limits of tumor EBV status; **Supporting =** PD-L1/immune-biology relationship, molecular-subgroup context, treatment-relevance hypothesis, general positive/negative result context; **Explicitly Excluded =** population EBV screening, EBV blood-serology algorithms, EBV vaccination/antiviral prevention, detailed EBER/ISH/PCR laboratory methodology, viral-load thresholds, PD-L1 testing/CPS, MSI/MMR testing, HER2 testing, CLDN18.2 testing, NGS methodology, immunotherapy treatment selection, hereditary risk assessment, germline/cascade testing, detailed histopathologic classification, individualized EBV-based prognosis; **Delegated-to PP =** PP-0178, PP-0179, PP-0180, PP-0181, PP-0182, PP-0183, PP-0184, PP-0187, PP-0189, PP-0190, PP-0191, PP-0212, PP-0213, PP-0149–PP-0159, Hereditary Gastric Cancer, Gastric Cancer Treatment.

# Final QA Decision

## PASS

PP-0168 satisfies the approved Decision Batch, Gold artifact specification, source-first evidence requirements, and adjacent-package boundary requirements.

# QA Final Status

# PASS — GOLD — READY FOR INTEGRATION
